Wordt geladen...
Identifying Regimens Containing TBI-166, a New Drug Candidate against Mycobacterium tuberculosis In Vitro and In Vivo
TBI-166, derived from riminophenazine analogues, is under development in a phase I clinical trial in China. TBI-166 showed more potent anti-tuberculosis (anti-TB) activity than did clofazimine in in vitro and animal experiments. To identify potent regimens containing TBI-166 in TB chemotherapy, TBI-...
Bewaard in:
| Gepubliceerd in: | Antimicrob Agents Chemother |
|---|---|
| Hoofdauteurs: | , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society for Microbiology
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6591646/ https://ncbi.nlm.nih.gov/pubmed/31061157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02496-18 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|